Literature DB >> 26915369

Neuroendocrine tumours in rare sites: differences in nomenclature and diagnostics-a rare and ubiquitous histotype.

Elia Guadagno1, Gaetano De Rosa1, Marialaura Del Basso De Caro1.   

Abstract

The diagnosis of neuroendocrine tumours in typical sites, as gastrointestinal tract and lung, is based upon well-coded criteria that have become familiar to most of the pathologists. Much more difficult is the recognition and allocation of proper nomenclature to be referred to the same histotype in locations where these tumours have a lower incidence. The aim of our review was to provide a quick handbook of the main diagnostic pitfalls known in literature that can interpose in the histopathological examination of neuroendocrine tumours in rare sites (urinary system and male genital organs, female genital organs, head and neck and breast). Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  DIAGNOSTICS; KI 67; Neuroendocrine

Mesh:

Year:  2016        PMID: 26915369     DOI: 10.1136/jclinpath-2015-203551

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Neuroendocrine neoplasms of the ovary: an analysis of clinicopathological characteristics and prognosis with a focus on histological grading.

Authors:  Wu Huang; Yiting Bao; Xukai Luo; Liangqing Yao; Lei Yuan
Journal:  Endocrine       Date:  2022-05-11       Impact factor: 3.925

2.  Differences in Characteristics and Outcomes Between Large-Cell Neuroendocrine Carcinoma of the Ovary and High-Grade Serous Ovarian Cancer: A Retrospective Observational Cohort Study.

Authors:  Li Pang; Zhiqiang Guo
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

3.  Small Cell Neuroendocrine Cervical Carcinoma: A Case Report.

Authors:  Malihe Hasanzadeh; Nooshin Babapour; Marjaneh Farazestanian; Farzaneh Hashem Niay Torshizi
Journal:  J Family Reprod Health       Date:  2020-12

4.  Novel Treatment of Small-Cell Neuroendocrine of the Vagina.

Authors:  Kathryn Kostamo; Mishka Peart; Nathalie McKenzie; Conisha Holloman; S J Carlan; Li Ge; John Maksem
Journal:  Case Rep Oncol Med       Date:  2018-02-04

Review 5.  Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues.

Authors:  Marco Gallo; Severo Campione; Valentina Di Vito; Nicoletta Fortunati; Fabio Lo Calzo; Erika Messina; Rosaria Maddalena Ruggeri; Antongiulio Faggiano; Annamaria Anita Livia Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-26       Impact factor: 5.555

6.  Primary neuroendocrine tumors of the ovary: Management and outcomes.

Authors:  Li Pang; Zhiqiang Guo
Journal:  Cancer Med       Date:  2021-11-12       Impact factor: 4.452

7.  PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.

Authors:  Xiaoyu Ji; Lei Sui; Kejuan Song; Teng Lv; Han Zhao; Qin Yao
Journal:  Cancer Med       Date:  2021-06-02       Impact factor: 4.452

8.  Neuroendocrine carcinoma of the cervix: a systematic review of the literature.

Authors:  Clemens B Tempfer; Iris Tischoff; Askin Dogan; Ziad Hilal; Beate Schultheis; Peter Kern; Günther A Rezniczek
Journal:  BMC Cancer       Date:  2018-05-04       Impact factor: 4.430

9.  Small Cell Carcinomas of the Uterine Cervix and Lung: Proteomics Reveals Similar Protein Expression Profiles.

Authors:  Tomomi Egawa-Takata; Kiyoshi Yoshino; Kosuke Hiramatsu; Satoshi Nakagawa; Satoshi Serada; Aya Nakajima; Hiroko Endo; Satoshi Kubota; Shinya Matsuzaki; Eiji Kobayashi; Yutaka Ueda; Eiichi Morii; Masahiro Inoue; Tetsuji Naka; Tadashi Kimura
Journal:  Int J Gynecol Cancer       Date:  2018-11       Impact factor: 3.437

10.  18F-FDG PET/computed tomography scan in patients with suspicion of recurrent neuroendocrine carcinoma of the cervix.

Authors:  Yuanyuan Jiang; Guozhu Hou; Li Huo; Fang Li; Zhaohui Zhu; Wuying Cheng
Journal:  Nucl Med Commun       Date:  2021-10-01       Impact factor: 1.690

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.